ArticleBritish journal of pharmacology2011
Phosphatidylinositol 3-kinase affects mitochondrial function in part through inducing peroxisome proliferator-activated receptor γ coactivator-1β expression.
Article in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Persistent PI3K-AKT signaling fortifies cellular defense against oxidative stress and ferroptosis through augmented mitochondrial fitness.Cellular & molecular biology letters · 2026Article
- Chrysoeriol-Mediated Neuroprotection in Parkinson's Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery.The Yale journal of biology and medicine · 2026Article
- Mitochondrial metabolism: A moving target in hepatocellular carcinoma therapy.Journal of cellular physiology · 2025Review
- Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound.ACS pharmacology & translational science · 2024Article
- Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms.The Journal of clinical investigation · 2024Article
- Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity.Journal of cancer research and clinical oncology · 2023Review
- Article
- Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages.Heliyon · 2023Article
- Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer - A Real-Life Experience.Biologics : targets & therapy · 2023Article
- Fisetin Attenuates Myocardial Ischemia-Reperfusion Injury by Activating the Reperfusion Injury Salvage Kinase (RISK) Signaling Pathway.Frontiers in pharmacology · 2021Article
- AdipoRon Protects Against Secondary Brain Injury After Intracerebral Hemorrhage via Alleviating Mitochondrial Dysfunction: Possible Involvement of AdipoR1-AMPK-PGC1α Pathway.Neurochemical research · 2019Article
- Impact of a novel phosphoinositol-3 kinase inhibitor in preventing mitochondrial DNA damage and damage-associated molecular pattern accumulation: Results from the Biochronicity Project.The journal of trauma and acute care surgery · 2017Article
- Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death.OncoTargets and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHyperactivation of phosphatidylinositol 3-kinase (PI3K), commonly observed in cancer, is believed to promote cancer cell growth and survival. Appropriate mitochondrial function is an integral part of cellular function. How PI3K affects mitochondrial homeostasis is not fully understood. EXPERIMENTAL APPROACH: Mitochondrial mass, membrane potential and reactive oxygen species (ROS) were quantified by three different fluorogenic probes. Gene expression at the levels of mRNA and protein were measured by quantitative RT-PCR and Western analysis. KEY
resultsUsing the PI3K inhibitors LY294002 and PI103, we found that suppressing PI3K activity altered mitochondrial function. Specifically, LY294002 and PI103 suppressed the mRNA expression levels of mitochondrial regulators nuclear respiratory factors 1 and 2 (NRF1 and NRF2). As NRF1 and NRF2 are under the transcriptional control of peroxisome proliferator-activated receptor γ coactivators-1α and -1β (PGC-1α and PGC-1β), we found that suppressing PI3K activity selectively reduced both the mRNA and protein levels of PGC-1β but not PGC-1α. Reducing PGC-1β expression also led to reduced mRNA expression levels of uncoupling protein 1, 2 (UCP1 and UCP2) and superoxide dismutase 2. Correspondingly, mitochondrial membrane potential (Δψ(m)) and ROS levels were increased. Finally, we partially blunted the LY294002-mediated growth suppression by using an antioxidant or over-expressing PGC-1β. CONCLUSIONS AND IMPLICATIONS: PI3K regulates mitochondrial homeostasis in part through PGC-1β and blocking this pathway induces ROS to arrest cell growth at the G₁ phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.